Biohaven showcases innovative neuroscience portfolio with 20 presentations at the 2024 american academy of neurology (aan) annual meeting and provides other business updates

Biohaven's first-in-class molecular degrader of extracellular proteins (mode™) technology targeting igg removal, bhv-1300, was selected for an oral presentation at aan highlighting its novel mechanism of action and the latest preclinical data demonstrating rapid, robust, and selective target removal biohaven announces it will present safety and igg lowering data from its ongoing single ascending dose (sad) study of bhv-1300 at the company's annual r&d day at the yale innovation summit in new haven, connecticut on may 29, 2024 safety, tolerability, and target engagement data showing the differentiated profile of bhv-7000 as a potential best-in-class kv7 activator will be presented as both oral and poster presentations; the phase 2/3 focal epilepsy program is now enrolling patients aan abstract of distinction awarded to bhv-2100, which demonstrated potent reversal of pain in preclinical models and favorable initial safety and pharmacokinetic data in phase 1 studies, highlighting the potential for trpm3 antagonism as a novel nonopioid target to treat pain and migraine oral and poster presentations of troriluzole as a novel glutamate modulating agent with favorable pharmacokinetics, safety, and outcomes data in the potential treatment of neurologic and neuropsychiatric disorders biohaven announces the data monitoring committee for its phase 3 trial in obsessive-compulsive disorder convened in the second quarter to review the interim analysis and informed the company that the study may continue additional efficacy and safety data regarding troriluzole in spinocerebellar ataxia will also be presented in both oral and poster format poster presentation of resilient phase 3 study design with taldefgrobep alfa in spinal muscular atrophy; study completed enrollment and topline results anticipated in the second half of 2024 biohaven announces the fda granted "rare pediatric disease" designation for taldefgrobep alfa thereby providing the potential to receive a priority review voucher (prv) if ultimately approved for the indication of spinal muscular atrophy other presentations and posters include development of the parcoms, a new outcome measure for parkinson's disease clinical trials, application of machine learning in video assessment of gait, and data demonstrating a reduced risk for parkinson's disease in patients taking anti-inflammatory agents three oral presentations and 6 poster presentations from the biohaven clinical and health outcomes group describe the development and validation of novel scales and natural history studies in support of troriluzole and bhv-8000 development programs, the impact of immune-modulating therapy in parkinson's disease, the burden of illness in focal epilepsy and kcnq2-dee (bhv-7000), and the application of ai machine learning technology to quantify patient mobility with troriluzole in spinocerebellar ataxia denver, co and new haven, conn. , april 13, 2024 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking